RE:BIG NEWS : Several Products down the pipeline
Cannabis develops CTI-091 therapy for joint pain
2014-08-18 10:39 ET - News Release
Mr. Craig Schneider reports
CANNABIS TECHNOLOGIES ANNOUNCES SECOND THERAPY -- CTI-091
Cannabis Technologies Inc. has developed a therapy containing a proprietary mixture of cannabinoids and non-cannabis-based active ingredients, CTI-091, for the relief of JOINT PAIN
and swelling associated with ARTHRITIS and joint disease. Preliminary laboratory studies showed CTI-091 suppresses the human macrophage interleukin-6, a major biomarker of inflammation, indicating strong scientific evidence that cannabis extracts reverse the disease progression.
CTI-091 is designed to enhance retention and absorption of the key ingredients around the target site and designed for the relief of JOINT PAIN and swelling.
Currently the formulation is in preclinical stage of development. The company is also WORKING to improve the delivery system to increase efficacy. It is expecting to go to initiate clinical phase 1 trials upon completion of these steps.
Craig Schneider, Cannabis Technologies president and chief executive officer, said: "We are extremely pleased to announce a second therapy in our expanding product pipeline. The pain and ARTHRITIStherapy takes our company to the next stage of development, reinforcing the proof of concept of our cannabinoid drug design platform. This platform is designed to effectively identify and fast-track new drug therapies. The company plans to have numerous therapies over the next 12 months within the product pipeline focusing on other areas like metabolic diseases (obesity and DIABETES), orphan diseases (Huntington's and epilepsy) as well as cancer and angiogenesis."
Pain and arthritis market
More than 46 million Americans have arthritis or a related disease, and some experts estimate the global market for arthritis drugs brings as much as $35-billion a year in profits. The many different types of drugs used to treat arthritis and its accompanying pain include over-the-counter and prescription-only drugs, with delivery methods of injections, infusions, patches and topical agents.
We seek Safe Harbor.
© 2014 Canjex Publishing Ltd. All rights reserved.